Diabetes medicine like Ozempic decrease most cancers dangers: Research

A category of diabetes drugs, which embody the best-selling drug Ozempic, are related to a decreased danger of sure obesity-related cancers, based on a examine launched Friday.

Printed within the journal JAMA, the examine in contrast sufferers with Sort 2 diabetes who had been handled with insulin versus sufferers who got a category of drug often called GLP-1 agonists, like Ozempic, between 2005 and 2018.

The researchers discovered that the sufferers who obtained GLP-1 agonists had a considerably decrease danger of growing 10 out of 13 cancers studied, together with kidney, pancreatic, esophageal, ovarian, liver and colorectal most cancers.

Among the many cancers which noticed no important change in danger had been thyroid most cancers and breast most cancers in postmenopausal girls.

“Weight problems is well-known to be related to a minimum of 13 most cancers varieties,” examine creator Rong Xu stated in an e-mail to AFP.

“Our examine gives proof that GLP-1RAs maintain promise in breaking the hyperlink between weight problems and most cancers,” Xu stated.

Among the many medicine studied had been semaglutide—commercially bought as Ozempic—in addition to liraglutide and others. Ozempic was accredited in america in 2017.

GLP-1 agonists have been round for about 20 years, however a brand new era of those medicine, amongst them Ozempic, has been popularized for his or her extra important weight reduction results.

Xu steered that the protecting advantages demonstrated within the examine could encourage medical doctors to prescribe GLP-1 therapies for diabetes sufferers as a substitute of different medicines like insulin.

© 2024 AFP